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Abstract
Cannabis is the most commonly used illicit drug worldwide. With debate surrounding the 
legalization and control of use, investigating its health risks has become a pressing area of 
research. One established association is that between cannabis use and schizophrenia, a 
debilitating psychiatric disorder affecting approximately 1% of the population over their lifetime. 
Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it 
remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or 
whether the same genes that increases psychosis risk may also increase risk of cannabis use.
In a sample of 2,082 healthy individuals, we show an association between an individual’s burden 
of schizophrenia risk alleles and use of cannabis. This was significant both for comparing those 
who have ever vs. never used cannabis (p=2.6×10−4), and for quantity of use within users 
(p=3.0×10−3). While directly predicting only a small amount of the variance in cannabis use, these 
findings suggest that part of the association between schizophrenia and cannabis is due to a shared 
genetic aetiology. This form of gene-environment correlation is an important consideration when 
calculating the impact of environmental risk factors, including cannabis use.
Introduction
During the last quarter of the 20th century cannabis use has increased to become the most 
widely used illicit drug in the world1. It is well established that cannabis use is much higher 
amongst schizophrenic patients than in the general population2. Cannabis intoxication can 
lead to an acute transient psychotic episode and produce short-term exacerbations of pre-
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existing psychotic symptoms3–5, an association that has been confirmed through the 
experimental administration of tetrahydrocannabinol (THC)6, 7. Meta-analyses of 
prospective studies have found that cannabis use increases the likelihood of developing a 
psychotic illness by a factor of roughly two8–11. A dose response effect has been 
demonstrated12–14, and use in adolescence has been associated with the greatest risk15. 
Given the large health burden from schizophrenia and other psychotic disorders16, the view 
that cannabis use is a component cause of schizophrenia has heavily influenced discussion 
over the legislation surrounding cannabis use.
However, the relationship between schizophrenia and cannabis use may be more 
complicated than it initially seems. Despite a clear association between the two, the 
possibility of reverse causation has not been entirely excluded. Some small studies have 
suggested that it is in fact psychosis that is a risk factor for cannabis use, as those on a 
psychotic spectrum are more likely to experiment with drugs17, 18. The strongest evidence 
comes from Ferdinand et al. who found that the association was bidirectional, as cannabis 
naïve children with prodromal psychotic episodes had greater incidence of later cannabis 
use19. However, a similarly sized study failed to replicate this finding20. There is also 
possibility of attempts at self-medication, as it has been suggested that cannabis use can 
reduce negative and affective symptoms in patients with an established psychotic 
disorder21–23.
The issue is further complicated by tentative evidence for interactions between cannabis use 
and genetic risk variants for schizophrenia24. Schizophrenia is known to be highly heritable 
with up to 80% of the variance explained by additive genetic effects25, and as sample sizes 
have increased a growing number of genetic risk variants have been identified26, 27. 
Interactions between risk variants and cannabis use might explain why some individuals 
experience psychosis while others do not. However, cannabis use itself has been reported to 
be heritable28–30, though no genetic risk variants have been identified31. It is unclear to what 
extent the heritability of cannabis use results from shared heritability with other behavioural 
phenotypes such as schizophrenia predicting its use.
Here we test for such genetic overlap directly, and aim to discern the direction of causation 
between cannabis use and schizophrenia. Within a sample of 2,082 healthy individuals, we 
tested to see if polygenic risk profiles for schizophrenia predict cannabis use. Polygenic risk 
profiles reflect the cumulative burden of risk alleles carried by an individual as identified in 
a previous genome-wide association study (GWAS)32, here of 13,833 schizophrenia cases 
and 18,310 controls27. Such an association with cannabis use would suggest that those 
genetically predisposed to schizophrenia use cannabis more frequently. This would mean 
that the association between schizophrenia and cannabis use is not simply one of an 
environmental risk factor, but rather involves gene-environment correlation as individuals 
choose and shape their own environment based on their own innate preferences.
Materials and Methods
The data used in this study come from the Australian Twin Registry. Data were obtained 
from two studies in which twins and their families participated in semi-structured diagnostic 
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telephone interviews aimed primarily at assessing psychiatric health. Informed consent was 
obtained from all participants.
Sample 1 consisted of 6,265 individuals aged between 23 and 39 years (mean = 29.9±2.5) 
interviewed between 1996 and 2000. Participants were members of the young adult cohort, a 
volunteer panel of twins born between 1964 and 1971. The interview was based upon a 
modified version of the SSAGA (Semi-Structured Assessment of the Genetics of 
Alcoholism33). Detailed information about the sample recruitment, the study procedure, and 
the measures can be found elsewhere34. Sample 2 comprised 9,688 individuals aged 
between 18 and 91 years (mean = 46.3±11.3) interviewed between 2001 and 2005. 
Participants were members of the older and younger adult cohort of Australian twin pairs 
(born between 1895 and 1964, and between 1964 and 1971, respectively). A subset of this 
sample was ascertained based on large sibship size, or having a relative with nicotine or 
alcohol dependence. The interview used for this sample was also based upon a modified 
version of the SSAGA. Further details about the sample and assessment can be found in 
Heath et al. (2011)35.
A subset of the participants (N=1,866; 11.7%) participated in both studies, in which case we 
used data from the last assessment. The combined phenotypic sample consisted of 14,087 
individuals, of whom 7,172 were genotyped. In both studies, twins were asked the same 
items about cannabis use: 1)Did you ever use marijuana?, 2) How old were you the very first 
time you tried marijuana (not counting the times you took it as prescribed)?, and 3) How 
many times in your life have you used marijuana (don’t count times when you used a drug 
prescribed for you, and took the prescribed dose). Ever use was measured on a dichotomous 
scale (ever versus never), whereas age at initiation and frequency of use were open 
questions. Table 1 shows the prevalence of cannabis use for individuals included in the 
present study.
Genotype data were obtained using three different Illumina single nucleotide 
polygmorphism (SNP) genotyping platforms (317K, HumanCNV370-Quadv3,Human 
CNV370v1 and Human610-Quad). Standard quality control procedures were applied as 
outlined previously36, including checks for ancestry outliers, Hardy–Weinberg equilibrium 
(p<10−6), Mendelian errors, call rate, genotypic missingness (>5%), individual missingness 
(>5%) and minor allele frequency (<0.01). Individuals were pruned on relatedness, 
removing one individual from each pair with relatedness greater than 0.05, as determined 
from genetic data. The final sample therefore comprised 2,082 ‘unrelated’ individuals (see 
Table 1 for sample details).
Polygenic risk profile scores were constructed using the p-values and log10 odds ratios from 
the most recent large genome-wide association study of schizophrenia, a meta-analysis of 
the Psychiatric Genomics Consortium’s studies with additional Swedish samples totaling 
13,833 cases and 18,310 controls27. SNPs were pruned for linkage disequilibrium using p-
value informed clumping in PLINK37, using a cut-off of R2 =0.25 within 200kb window. 
The MHC region of the genome was excluded, due to its complex linkage disequilibrium 
structure. After linkage disequilibrium pruning 147,830 SNPs remained. Multiple scores 
were generated for each individual using the PLINK --score option and based on top SNPs 
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from the schizophrenia GWAS using varying significance thresholds (p=0.0001, 0.001, 
0.01. 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, and 1.0). Polygenic risk profile scores were tested for 
association with a binary ever vs. never used cannabis and two quantitative traits for 
quantity of use and age at first use, in logistic and linear regressions respectively. These 
analyses were corrected for the first 10 ancestry-informative principal components, 
genotyping platform, sex, age, age squared, and sex-by-age. Analysis was performed in 
STATA38.
Results
After pruning, 2,082 unrelated individuals remained in our sample with both genotype and 
phenotype measures. Within the sample, 1,011 individuals (48.6%) had ever used cannabis, 
of whom 997 had data on quantity of use. Mean number of usages of cannabis over lifetime 
was 62.7 (95% CI 53.8–71.6), and the mean age of initiation of use was 20.1 (95% CI 19.7–
20.5). Males showed higher rates of use than females, at 53.5% compared to 43.9% 
(p<0.001), though no difference in age at initiation. Table 1 shows the summary statistics for 
the samples.
Polygenic risk scores for schizophrenia showed positive associations for ever vs. never use 
of cannabis across all p-value thresholds, with the strongest association for those SNPs with 
p-values below 0.01 in the original schizophrenia GWAS (see Figure 1, R2=0.47%, 
p=2.6×10−4). Significant associations were also seen in the analysis of quantity of cannabis 
use for 9 of the 10 SNP cut-offs, with the top association seen for those SNPs with p≤0.05 
for schizophrenia (R2=0.85%, p=0.003). No association was seen with age at initiation of 
use, though the association with quantity of use remained significant when number of years 
of usage was accounted for (results not shown).
As a secondary analysis, polygenic risk score for schizophrenia risk alleles with p<0.01 (the 
threshold with the greatest association in the primary analysis) were examined within 990 
twin pairs (608 dizygotic and 382 monozygotic) where data on cannabis use of both twins 
was available. Taking the mean polygenic risk score within each twin pair, an ordinal 
regression was performed to predict whether neither (n=272), one (n=273), or both twins 
(n=445) were cannabis users. After correcting for age, sex, and zygosity, a significant 
association was observed (p=0.001). Those twin pairs where both reported using cannabis 
had the greatest burden of schizophrenia risk alleles, pairs with only one user were found to 
have an intermediate level, and the lowest burden was found in pairs where neither twin 
reported use (see Figure 2).
Discussion
Our results show that to some extent the association between cannabis and schizophrenia is 
due to a shared genetic aetiology across common variants. They suggest individuals with an 
increased genetic predisposition to schizophrenia are both more likely to use cannabis and to 
use it in greater quantities. This is not to say there is no causal relationship between use of 
cannabis and risk of schizophrenia, but it does establish that at least part of the association 
may be due to causal relationship in the opposite direction. While the variance in cannabis 
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use explained by schizophrenia polygenic risk profiles is small, it is in line with other cross-
phenotype analyses, largely due to the polygenic risk scores for schizophrenia predicting 
only ~7% of the variation for schizophrenia itself. Previous associations between polygenic 
risk scores for schizophrenia and other psychiatric illnesses, such as bipolar disorder, major 
depression and autism39, have shown effects of similar sizes. Further research will be 
needed to see if the genetic overlap observed here is specific to cannabis use or is present 
across illicit drug use and addiction phenotypes, data for which was not widely available in 
this sample. For now, these findings have important implications for the current perception 
of cannabis use as a risk factor for schizophrenia, and other psychotic disorders.
It is important to emphasise that the implication of schizophrenia risk alleles predicting 
cannabis use, if true, does not rule out the possibility of cannabis independently being a risk 
factor for schizophrenia. A bi-directional association between cannabis use and psychosis 
has previously been suggested40. Further, one caveat to interpreting the direction of 
causation concerns the discovery sample used to identify schizophrenia risk alleles. The 
schizophrenia GWAS sample will likely include many more cannabis users among cases 
than controls. This may lead to an excess of causal SNPs associated with cannabis use, as 
opposed to schizophrenia itself, identified as schizophrenia risk alleles. Only if the discovery 
schizophrenia sample was comprised entirely of non-cannabis users could causation be 
inferred without any risk of confounding. This is an important consideration as to whether 
polygenic risk scores over-estimate individuals’ un-modifiable genetic risk by including 
their genetic predisposition to modifiable environmental risk factors.
These results highlight the blurring between behavioural phenotypes and environment, and 
have wider implications for how we perceive supposedly environmental risks for disease. 
Individuals select their own environments based on their innate and learned preferences, and 
have their environments react to their own behaviour. Further, parents pass down both genes 
and environment to their children. All of these can contribute to gene-environment 
correlation, particularly with respect to behavioural traits. Several studies have shown that 
supposedly environmental risk factors such as urbanicity, religiosity, and stressful life events 
have heritable components to them41–43. The existence of heritability for supposedly 
environmental risk factors does not mean they are inevitable, only that causality is more 
complicated to discern. Future studies will need to explore the matching of cases and 
controls on environmental risk variants in order to fully disentangle causation. This can be 
supplemented exploring the generating of polygenic risk scores for environmental risk 
factors, and their role in predicting disease status. The wider availability of genetic data in 
richly phenotyped samples should allow for the integration of genetics into an 
epidemiological framework, and so the discovery of gene-environment correlations where 
they exist.
With ongoing debate over the legalisation of cannabis and the potential health risks it poses, 
understanding the association between its use and schizophrenia is a priority. It has 
previously been suggested that, even assuming an entirely causal relationship, the required 
reduction in the number of cannabis users to prevent one case of schizophrenia is in the 
thousands44. Our findings here highlight the possibility that this association might be 
bidirectional in causation, and that the risks of cannabis use could be over-estimated. This is 
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an important subtlety to consider when calculating the economic and health impact of 
cannabis use.
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Figure 1. 
Results of polygenic risk scores for schizophrenia predicting variance explained (R2) in 
cannabis use as both a binary trait of ever vs. never, and as a quantitative trait of lifetime 
usewithin only users. Polygenic scores were created using different cut-offs for the inclusion 
of risk variants for schizophrenia, ranging from p=0.0001 to 1.0.
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Figure 2. 
Mean standardized polygenic risk scores for pairs of twins when neither (n=272), one 
(n=273), or both twins (n=445) had reported use of cannabis. An ordinal regression reported 
a significant association (p=0.001).
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Table 1
Summary statistics of sample for cannabis use traits
Users Non-users
N 1,011 1,071
Mean age (SE) 41.3 (.23) 53.0 (.37)
Percentage female (%) 46.5 56.0
Mean age at initiation (SE) 19. 6 (.06) -
Mean number of uses over life (SE) 62.7(4.56) -
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